Gopal, A., Trneny, M., Sehn, L., Wu, J., Arbushites, M., Bortolami, O., Luminari, S. (2025). Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of patients receiving second-line treatment. Blood. https://doi.org/10.1182/blood-2025-1819